ALNOV:EPA
Novacyt SA
0,51 €
arrow_downward
−6,72%(−0,037) 1 d
13 aug., 17:35:21 GMT+2 · EUR
search
Alla symboler
1 d
5 d
1 m
6 m
Hittills i år
1 år
5 år
MAX
| Symbol | Pris | Ändring | Ändring i procent |
|---|
insights_autoGenererar de viktigaste insikterna för ALNOV …
Öppen
0,54 €
Högt
0,56 €
LÃ¥gt
0,51 €
Börsvärde
37,40Â mn
Genomsn. vol.
171,02Â tn
Volym
1,14Â mn
52v högst
1,04 €
52v lägst
0,29 €
EPS
−0,39 €
Utestående aktier
72,59Â mn
Antal anställda
216
Öppen
0,54 €
Högt
0,56 €
LÃ¥gt
0,51 €
Börsvärde
37,40Â mn
Genomsn. vol.
171,02Â tn
Volym
1,14Â mn
52v högst
1,04 €
52v lägst
0,29 €
EPS
−0,39 €
Utestående aktier
72,59Â mn
Antal anställda
216
Profil
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Om Novacyt SA
AI-innehåll kan innehålla fel. Läs mer